This small cap up big after AstraZeneca investment

And complimentary training now 👀                                                                                                                                                                                                                                                                                                                                                                                                                 November 01, 2023 | [Read Online]( Good day, 360 – Here are our top investing ideas today – these setups look primed!And JW’s chat room is open NOW, see FOMO below. Be the best prepared trader on the Street!  CLLS - Up over 150% in pre-market after announcing strategic collaboration with AstraZeneca PSTV - Up over 16% in pre after earnings beat and $500,000 share repurchase program MNPR - Up over 40% in pre after presenting data showing a tumor reduction benefit Moneyballing the SPY (NOW)! Don't miss Jeff Williams’ LIVE, complimentary trading session at 9AM EST TODAY (NOW), focusing on how to use a straightforward strategy to trade ONE STOCK. He [ran the stats]( and had best results staying in a trade two hours or less 👀 *NOTE: trading is hard, results not guaranteed and should not be expected to be replicated by typical subscribers [Join Room to hear more from 9-11AM EST!]( OR (SPECIAL) [Encore](👏[7pm EST]( And then sign up for a SPECIAL Market Navigator Trial (ENDING TONIGHT)! [$27 Trial Ends TONIGHT](! CLLS - Up over 150% in pre-market after announcing strategic collaboration with AstraZeneca Cellectis (CLLS) is a clinical stage biotechnological company that develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. This morning [it was announced]( that CLLS would begin a strategic collaboration with AstraZeneca. The collaboration leverages Cellectis' gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate products. As part of the strategic collaboration and investment CLLS is to receive up to $245M in cash (up to $220M equity investment and $25M upfront payment), with potential for additional milestones, plus tiered royalties. The stock is trading up over 150% in pre-market this morning after the news. The $2.34 area was initially resistance in the pre-market and has since begun to act as support. Above it, targets to the upside are $2.54, and then the pre-market high at $2.79. Beyond that, $3, $3.40 and $4 come into play. Below $2.34, there is potential support at $2.20, $2.04, $1.75, $1.40 and then a gap to fill at $0.97. PSTV - Up over 16% after earnings beat and $500,000 share repurchase program Plus Therapeutics (PSTV) is a clinical-stage pharmaceutical company that focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. In the after-hours yesterday, the [company announced]( Q3 earnings of -$1.00 vs -$2.85 the previous year and revenue of $1.24million vs $1.29 million expected. The company also approved a $500k share repurchase program. The stock is trading up over 16% in pre-market after the earnings release. The $1.40 level has acted as support in the pre-market and will be an important area to watch. Above it, targets to the upside are $1.50, $1.58 and then the pre-market high at $1.63. Beyond that, $2, $2.60 and $3 come into play. Below $1.40, there is potential support at $1.34, $1.24 and a gap fill at $1.22. MNPR - Up over 40% in pre after presenting data showing a tumor reduction benefit Monopar Therapeutics (MNPR) is a clinical-stage biopharmaceutical company that engages in developing therapeutics for the treatment of cancer in the United States. This morning, the [company announced]( that it will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of Camsirubicin in patients with advanced soft tissue sarcoma (ASTS) later today at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting. The results show a tumor reduction benefit. The stock traded up over 40% in pre-market after the news. The $0.59 level found buyers after the news and is now a potential area of support. Above it, targets to the upside are $0.65, $0.70 and then the pre-market high at $0.7428. Beyond that, $0.80 and $1 come into play. Below $0.59, there is potential support at $0.50 and then a gap to fill at $0.43. [Economic Calendar]( To Your Success!  Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at [( FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 2023 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States of America